Mitoxantrone Recruiting Phase 3 Trials for Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation Treatment

IndicationsStatusPurposePhase
RecruitingTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT03182244A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FLT3 Mutation